TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast
Purpose To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast. Patients and methods Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter....
Gespeichert in:
Veröffentlicht in: | Journal of endocrinological investigation 2018-11, Vol.41 (11), p.1301-1306 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1306 |
---|---|
container_issue | 11 |
container_start_page | 1301 |
container_title | Journal of endocrinological investigation |
container_volume | 41 |
creator | Pirola, I. Gandossi, E. Brancato, D. Marini, F. Cristiano, A. Delbarba, A. Agosti, B. Castellano, M. Cappelli, C. |
description | Purpose
To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast.
Patients and methods
Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months.
Results
At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively (
p
= 0.455).
Conclusions
This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance. |
doi_str_mv | 10.1007/s40618-018-0867-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2019046956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2123083047</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq0KVC7tA3RTWWLDJnB8i50lQoVBGolFp2vLk5zMhCbxYCeIeZs-C0-GR5lChdTFkS__d34f-SfkG4MLBqAvo4ScmQx2ZXKdiU_kmGkOmREmP_hnf0ROYnwAEFoY_Zkc8UIZLqQ8Jt3i54zik2tHNzS-p01P19uNH9bb4JuKbtIt9kOkLsaxa_oVbZvHMQktPk3Qc9MjdQNdBnS_axcH6gMV8PIn0XSJtQ_4rn0hh7VrI37dr6fk182PxfUsm9_f3l1fzbOSGy0ypiqppStVLXMoVVUyhSodHeOqLFCic9oIYQB1DjlAVbCiWCpulKgqWQtxSs4n303wjyPGwXZNLLFtXY9-jJYDK0DmhcoTevYBffBj6NN0ljMuwAiQOlFsosrgYwxY201oOhe2loHdZWGnLCzsKmVhd0N83zuPyw6rt46_n58APgExSf0Kw_vT_3d9BTxJlSk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2123083047</pqid></control><display><type>article</type><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</creator><creatorcontrib>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</creatorcontrib><description>Purpose
To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast.
Patients and methods
Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months.
Results
At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively (
p
= 0.455).
Conclusions
This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</description><identifier>ISSN: 1720-8386</identifier><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/s40618-018-0867-3</identifier><identifier>PMID: 29582344</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Body weight ; Breakfast ; Drug Administration Schedule ; Endocrinology ; Fasting ; Female ; Goiter ; Hormone Replacement Therapy ; Humans ; Hypothyroidism ; Hypothyroidism - blood ; Hypothyroidism - drug therapy ; Male ; Medicine ; Medicine & Public Health ; Metabolic Diseases ; Middle Aged ; Original Article ; Thyroid ; Thyroid gland ; Thyroid-stimulating hormone ; Thyroidectomy ; Thyroiditis ; Thyrotropin - blood ; Thyroxine ; Thyroxine - administration & dosage ; Thyroxine - therapeutic use ; Treatment Outcome</subject><ispartof>Journal of endocrinological investigation, 2018-11, Vol.41 (11), p.1301-1306</ispartof><rights>Italian Society of Endocrinology (SIE) 2018</rights><rights>Copyright Springer Science & Business Media 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</citedby><cites>FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40618-018-0867-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40618-018-0867-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29582344$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pirola, I.</creatorcontrib><creatorcontrib>Gandossi, E.</creatorcontrib><creatorcontrib>Brancato, D.</creatorcontrib><creatorcontrib>Marini, F.</creatorcontrib><creatorcontrib>Cristiano, A.</creatorcontrib><creatorcontrib>Delbarba, A.</creatorcontrib><creatorcontrib>Agosti, B.</creatorcontrib><creatorcontrib>Castellano, M.</creatorcontrib><creatorcontrib>Cappelli, C.</creatorcontrib><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><title>Journal of endocrinological investigation</title><addtitle>J Endocrinol Invest</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Purpose
To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast.
Patients and methods
Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months.
Results
At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively (
p
= 0.455).
Conclusions
This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</description><subject>Adult</subject><subject>Body weight</subject><subject>Breakfast</subject><subject>Drug Administration Schedule</subject><subject>Endocrinology</subject><subject>Fasting</subject><subject>Female</subject><subject>Goiter</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Hypothyroidism</subject><subject>Hypothyroidism - blood</subject><subject>Hypothyroidism - drug therapy</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Diseases</subject><subject>Middle Aged</subject><subject>Original Article</subject><subject>Thyroid</subject><subject>Thyroid gland</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroidectomy</subject><subject>Thyroiditis</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine</subject><subject>Thyroxine - administration & dosage</subject><subject>Thyroxine - therapeutic use</subject><subject>Treatment Outcome</subject><issn>1720-8386</issn><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq0KVC7tA3RTWWLDJnB8i50lQoVBGolFp2vLk5zMhCbxYCeIeZs-C0-GR5lChdTFkS__d34f-SfkG4MLBqAvo4ScmQx2ZXKdiU_kmGkOmREmP_hnf0ROYnwAEFoY_Zkc8UIZLqQ8Jt3i54zik2tHNzS-p01P19uNH9bb4JuKbtIt9kOkLsaxa_oVbZvHMQktPk3Qc9MjdQNdBnS_axcH6gMV8PIn0XSJtQ_4rn0hh7VrI37dr6fk182PxfUsm9_f3l1fzbOSGy0ypiqppStVLXMoVVUyhSodHeOqLFCic9oIYQB1DjlAVbCiWCpulKgqWQtxSs4n303wjyPGwXZNLLFtXY9-jJYDK0DmhcoTevYBffBj6NN0ljMuwAiQOlFsosrgYwxY201oOhe2loHdZWGnLCzsKmVhd0N83zuPyw6rt46_n58APgExSf0Kw_vT_3d9BTxJlSk</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Pirola, I.</creator><creator>Gandossi, E.</creator><creator>Brancato, D.</creator><creator>Marini, F.</creator><creator>Cristiano, A.</creator><creator>Delbarba, A.</creator><creator>Agosti, B.</creator><creator>Castellano, M.</creator><creator>Cappelli, C.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20181101</creationdate><title>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</title><author>Pirola, I. ; Gandossi, E. ; Brancato, D. ; Marini, F. ; Cristiano, A. ; Delbarba, A. ; Agosti, B. ; Castellano, M. ; Cappelli, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2873-15d474ac5f460c5dc15e5ac5a125c9e4eaa783380e760600d9199b52853dd4f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Body weight</topic><topic>Breakfast</topic><topic>Drug Administration Schedule</topic><topic>Endocrinology</topic><topic>Fasting</topic><topic>Female</topic><topic>Goiter</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Hypothyroidism</topic><topic>Hypothyroidism - blood</topic><topic>Hypothyroidism - drug therapy</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Diseases</topic><topic>Middle Aged</topic><topic>Original Article</topic><topic>Thyroid</topic><topic>Thyroid gland</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroidectomy</topic><topic>Thyroiditis</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine</topic><topic>Thyroxine - administration & dosage</topic><topic>Thyroxine - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pirola, I.</creatorcontrib><creatorcontrib>Gandossi, E.</creatorcontrib><creatorcontrib>Brancato, D.</creatorcontrib><creatorcontrib>Marini, F.</creatorcontrib><creatorcontrib>Cristiano, A.</creatorcontrib><creatorcontrib>Delbarba, A.</creatorcontrib><creatorcontrib>Agosti, B.</creatorcontrib><creatorcontrib>Castellano, M.</creatorcontrib><creatorcontrib>Cappelli, C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pirola, I.</au><au>Gandossi, E.</au><au>Brancato, D.</au><au>Marini, F.</au><au>Cristiano, A.</au><au>Delbarba, A.</au><au>Agosti, B.</au><au>Castellano, M.</au><au>Cappelli, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J Endocrinol Invest</stitle><addtitle>J Endocrinol Invest</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>41</volume><issue>11</issue><spage>1301</spage><epage>1306</epage><pages>1301-1306</pages><issn>1720-8386</issn><issn>0391-4097</issn><eissn>1720-8386</eissn><abstract>Purpose
To compare TSH levels of hypothyroid patients treated with liquid LT4 at breakfast or 30 min before breakfast.
Patients and methods
Subjects, aged 18–75 years old, were eligible if they presented hypothyroidism, due to Hashimoto’s thyroiditis or after thyroidectomy for proven benign goiter. Seven hundred ninety-eight patients were recruited and enrolled in the study. Thirty-seven subjects withdrew from the trial. A total of 761 patients (mean age 46.2 ± 10.8 years) completed the study. The starting dose of LT4 was determined through clinical judgment, taking into account TSH levels, estimated residual thyroid function, age, body weight and comorbidities. All patients underwent TSH, fT4, and fT3 evaluation to verify achievement of euthyroidism with their initial fasting state assumption of LT4 after 8 weeks of therapy. If euthyroidism was not achieved, an appropriately adjusted LT4 dose was administered for 8 weeks, after which thyroid function parameters were checked again. If euthyroidism was achieved, the patients were asked to take LT4 at breakfast and hormone levels were checked again after 6 months.
Results
At the end of the study period, no significant differences in serum TSH level were observed whether LT4 was ingested at breakfast or 30 min prior in a fasting state: 2.61 ± 1.79 vs. 2.54 ± 1.86 mIU/L, respectively (
p
= 0.455).
Conclusions
This study confirms in a large set of patients that a liquid LT4 formulation can be taken directly at breakfast and potentially improve therapeutic compliance.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>29582344</pmid><doi>10.1007/s40618-018-0867-3</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1720-8386 |
ispartof | Journal of endocrinological investigation, 2018-11, Vol.41 (11), p.1301-1306 |
issn | 1720-8386 0391-4097 1720-8386 |
language | eng |
recordid | cdi_proquest_miscellaneous_2019046956 |
source | MEDLINE; SpringerLink Journals |
subjects | Adult Body weight Breakfast Drug Administration Schedule Endocrinology Fasting Female Goiter Hormone Replacement Therapy Humans Hypothyroidism Hypothyroidism - blood Hypothyroidism - drug therapy Male Medicine Medicine & Public Health Metabolic Diseases Middle Aged Original Article Thyroid Thyroid gland Thyroid-stimulating hormone Thyroidectomy Thyroiditis Thyrotropin - blood Thyroxine Thyroxine - administration & dosage Thyroxine - therapeutic use Treatment Outcome |
title | TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A23%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TSH%20evaluation%20in%20hypothyroid%20patients%20assuming%20liquid%20levothyroxine%20at%20breakfast%20or%2030%C2%A0min%20before%20breakfast&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=Pirola,%20I.&rft.date=2018-11-01&rft.volume=41&rft.issue=11&rft.spage=1301&rft.epage=1306&rft.pages=1301-1306&rft.issn=1720-8386&rft.eissn=1720-8386&rft_id=info:doi/10.1007/s40618-018-0867-3&rft_dat=%3Cproquest_cross%3E2123083047%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2123083047&rft_id=info:pmid/29582344&rfr_iscdi=true |